Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Avant, Celldex deal

AVAN and Celldex will merge in a stock deal valued at about $115 million based on AVAN's close of $0.55 on Oct. 19, the last trading day before the deal was

Read the full 316 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE